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     Hyperlipidemia is a consistent feature of the 
nephrotic syndrome (NS) and is usually of the Ha or 
lib Fredrickson type. In cases with severe 
hypoalbuminemia (15g/l or less) very low density 
lipoproteins (VLDL) also increase and the ratio of 
cholesterol to.triglyceride falls (1-4). The nephrotic 
hyperlipidemia is generally considered to be due to 
increased hepatic synthesis and secretion of lipopro- 
teins, but there are also investigations showing al- 
tered lipoprotein clearance (1,2). Warwick et al. (5) 
have found a trend towards lower fractional cata- 
bolic rate of intermediate density lipoproteins (IDL) 
and low density lipoproteins (LDL) in nephrotic 
patients with relatively well maintained serum albu- 
min despite the heavy proteinuria. In another group 
of nephrotic pateints with lower plasma albumin 
levels, the amount of LDL cleared by receptor- 
mediated endocytosis (RME) was only 55% of the 
value seen in controls, while 60% more LDL were 
channeled into alternative catabolic pathways (6). In 
experimental NS, delayed removal of chylomicron 
remnants was revealed as well (7). Chylomicron 
remnants are taken up by the liver via the LDL 
receptor-related protein (LRP). Recently, evidences 
were provided that receptor for activated <x,-macro- 
globulin (a2-macroglobulin-proteinase complex) and 
the LRP are one and the same entity (8). <x,-macro- 
globulin seems to control the activity of proteinases 
not by active site-directed inhibition but by steric 
shelding and rapid clearance (9). The plasma levels 
of a2-macroglobulin are consistently elevated in NS 
(2), but to the best of my knowledge, there are 
insufficient data about the uptake of oc2-macroglobu- 
lin-proteinase complexes. Asamietal. (10) reported 
a glomerular deposition of a2-macroglobulin in a 
child with steroid refractory NS, but such deposi- 
tions were not detected in other nephrotic patients. 
Biochemical and clinical improvement was observed 
in this case after treatment with the synthetic protei- 
nase inhibitor camostat mesylate, but the dynamics of 
a2-macroglobulin depositions was not examined. 
The precise disturbances responsible for the re- 
duced RME of LDL or chylomicron remnants is NS 
are still unclarified (2). In addition to quantitative, 
there are also qualitative changes in the lipoproteins 
of nephrotic subjects (1,2), but Kramer et al (11) 
have established on cultured human glomerular cells 
and fibroblasts not reduced binding and internaliza- 
tion of LDL and increased uptake of IDL isolated 
from nephrotic patients. To the bast of my knowl- 
edge, the number of IDL receptors in nephrotic 
subjects is still not studied. In the investigations 
reporting not significant differences in the catabolic 
rate of LDL in NS, the receptor-dependent and the 
receptor-independent pathways have not been ex- 
amined separately (1,2). 
Capillaries are permeable to water and electrolytes, 




are responsible for the existence of the oncotic 
pressure gradient across the capillary wall. In NS, 
hypoalburninemia results both from a loss into the 
urine and an increase in the fractional catabolic rate. 
The fall in the plasma oncotic pressure increases the 
water filtration across the capillaries. This leads to a 
rise in the lymph flow and the return of fluid from the 
lymphatic system to the circulation. Because the 
filtered fluid has low protein content, the concentra- 
tion of albumin in the interstitial fluid, normally 
about 50% of that in the serum, falls. By this mecha- 
nism, in the nephrotic subjects the oncotic pressure 
gradient changes little although the considerable 
decrease in plasma albumin (12,13). Koomans et al 
(14) have established that when plasma oncotic 
pressure falls from 23mmHg to 1 OmmHg, the oncotic 
pressure gradient dropped by only 2-3mmHg (from 
10 to 7-8mmHg), i.e., the interstitial oncotic pres- 
sure has remained only 2-3mmHg. This results are 
supported by earlier investigations showing very 
low protein content of the edema fluid obtained from 
nephrotic subjects (1-5 g/1) (15) or about 80% reduc- 
tion of the tissue albumin levels (16). The lymph 
flow is greatly enhanced in NS and when tissue 
albumin is almost washed out edema formation 
takes place (13). Serum sodium concentrations in 
nephrotic patients appear to be not significantly 
different from controls (17). 
There is no consent about the cause of nephrotic 
hyperlipidemia and both proteinuria and hypoalbu- 
minemia have been implicated in its pathogenesis 
(1,2). In NS, hyperlipoproteinemia shows an inverse 
correlation with serum albumin and there is evi- 
dence that thisj correlation reflects changes in the 
plasma erMfOtic pressure (1,2). Baxter et al (18) and 
Alien et al (19) have demonstrated that infusions of 
albumin or other osmotically active substances sig- 
nificantly reduce the plasma levels of cholesterol 
and triglycerides in nephrotic subjects and that these 
effects are not due to changes in the lipoprotein 
lipase activity.  
It has been established in vitro that hypotonic media 
inhibits RME by creating unusually flat clathrin 
lattices (20, and reviewed in 21). 
In my option, the data presented above poses two 
interesting questions: (i)  is lowered oncotic pres- 
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